Sialylation inhibition can partially revert acquired resistance to enzalutamide in prostate cancer cells

Goode, E.A., Orozco-Moreno, M. orcid.org/0000-0002-6180-7882, Hodgson, K. orcid.org/0000-0003-4348-0430 et al. (10 more authors) (2024) Sialylation inhibition can partially revert acquired resistance to enzalutamide in prostate cancer cells. Cancers, 16 (17). 2953. ISSN 2072-6694

Abstract

Metadata

Item Type: Article
Authors/Creators:
Copyright, Publisher and Additional Information:

© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).

Keywords: prostate cancer; castrate resistance; enzalutamide; sialic acid; sialyltransferase inhibitor; combination therapies
Dates:
  • Published: 1 September 2024
  • Published (online): 24 August 2024
  • Accepted: 22 August 2024
  • Submitted: 18 July 2024
Institution: The University of Sheffield
Academic Units: The University of Sheffield > Faculty of Medicine, Dentistry and Health (Sheffield) > School of Medicine and Population Health
Depositing User: Symplectic Sheffield
Date Deposited: 09 Sep 2024 14:41
Last Modified: 09 Sep 2024 14:41
Status: Published
Publisher: MDPI AG
Refereed: Yes
Identification Number: 10.3390/cancers16172953
Open Archives Initiative ID (OAI ID):

Export

Statistics